Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 5(4): 335-352.

Author(s): P. F. Mannaioni, V. Fabbroni, R. Mastroianni and E Masini.

Affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, V.le G.Pieraccini n.6,50139, Florence, Italy.


Non-steroidal anti-inflammatory drugs (NSAIDs) are a structurally diverse group of similarly acting compounds that are widely prescribed and used for the management of pain associated with inflammatory conditions. Our present aim is to choose a leading drug for each class of NSAIDs, and to discuss the debated issues still pending about that drug, in order to weigh the risk/benefit ratio according to the current hypotheses on its mode of action. The leading compounds of the past and present which we have selected within this framework are aspirin, acetaminophen, celecoxib and rofecoxib. The discovery of nitric oxide (NO) in the last decade has resulted in proposing new NO-donors. Particularly interesting in this area has been the synthesis of NO-releasing anti-inflammatory drugs. The addition of NO to aspirin and to other NSAIDs has resulted in molecules that maintain their inhibitory effects on the cyclooxygenases (COX) but are devoid of cardiovascular, renal and gastrointestinal toxicity. The purpose of this review is also to update the “state-of-theart” of new classes of anti-inflammatory drugs such as COX-inhibiting nitric oxide donors (CINODs) and carbon monoxide (CO) releasing molecules (CO-RMs) as future tools in the therapy of inflammation and cellular proliferation.


NSAIDS, aspirin, paracetamol, rofecoxib, NO-releasing NSAIDs, CINODs, CO-RMs.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 5
Issue Number: 4
First Page: 335
Last Page: 352
Page Count: 18
DOI: 10.2174/187152306778772865
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: urooj@benthamscience.org Copyright © 2017 Bentham Science